Selective BCRP / ABCG2 transporter inhibitors as agents for eliminating anticancer drug resistance
By developing new compounds and using alkylation and amide formation steps, the problems of low solubility and insufficient selectivity of existing BCRP/ABCG2 inhibitors were solved, efficient inhibitory effect and low toxicity were achieved, and production costs were reduced, and the production costs were solved. Issues of resistance to anti-cancer drugs on the market.
Patent Information
- Application Number
- CN202080053589.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-07-25
- Filing Date
- 2020-06-01
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-06-01
AI Technical Summary
Existing BCRP/ABCG2 inhibitors such as Ko143 have problems with low solubility, insufficient cell selectivity and high synthesis complexity, which leads to poor effectiveness in clinical applications and the lack of rapidly renewed anti-cancer drugs in the market, resulting in chemical resistance. Sexual problems are becoming increasingly serious.
A new compound has been developed to prepare BCRP/ABCG2 inhibitors with high selectivity and low cytotoxicity through specific alkylation, ester functional hydrolysis and amide formation steps, which can be used in combination with anticancer drugs to enhance Treatment effect and reduce drug resistance.
The new compounds show better inhibitory activity and selectivity, reduce cytotoxicity, and reduce production costs by simplifying the synthesis route and improving yield, effectively solving the drug resistance problem and enhancing the role of anti-cancer drugs.
Smart Images

Figure CN114206904B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to novel compounds, methods for their production and their use as BCRP / ABCG2 inhibitors. Background Art
[0002] These new organic compounds all belong to the same chemical family, which is derived from natural compounds: chromones.
[0003] Their main purpose is to selectively inhibit the BCRP protein (breast cancer resistance protein), also known as ABCG2, which is involved in the phenomenon of multidrug resistance of tumors to anticancer agents. BCRP acts as an efflux pump and is overexpressed in tumor cell membranes. These compounds act as selective, non-cytotoxic inhibitors of BCRP / ABCG2.
[0004] Finally, these compounds have better inhibitory activity and better selectivity than the reference compound Ko143, and are less cytotoxic, while having a simpler organic synthesis. In the clinic, these compounds could be used as adjuvants in combination with anticancer drugs to enhance the effects of the latter and counteract the resistance of tumors to treatments that eradicate them.
[0005] According to the World Health Organization, cancer is the second leading cause of death in the world, killing nearly 9.6 million people each year. The annual cost of treating the disease was estimated to be $1,160 billion in 2010. Currently, there are three main strategies for treating cancer, depending on the stage and type of cancer: 1) surgery, 2) radiation therapy, and 3) chemotherapy. It should be noted that these strategies can be used in conjunction with each other to supplement the overall effectiveness of the treatment.
[0006] However, in chemotherapy, repeated use of the same anticancer agent can cause tumor cells to respond to it in a protective and defensive manner. Unfortunately, this can also cause tumors to be insensitive to a variety of anticancer drugs, making chemotherapy ineffective and increasing harm to patients. One of the defenses established by tumor cells includes overexpression of transmembrane proteins called ATP-binding cassette (ABC) transporters in the cell membrane. (Borst, P.; Elferink, R. O. Malmammalian ABC Transporters in Health and Disease. Annu. Rev. Biochem. 2002, 71 (1), 537-592. Linton, K. J. Structure and Function of ABC Transporters. Physiology 2007, 22 (2), 122-130. Sharom, F. J. ABC Multidrug Transporters: Structure, Function and Role in Chemoresistance. Pharmacogenomics 2008, 9 (1), 105-127.).
[0007] It has been clearly identified that three of the 48 transmembrane proteins in this superfamily play a major role in chemotherapy failure: P-gp / ABCB1, MRP1 / ABCC1 and BCRP / ABCG2 (Leslie, EM; Deeley, RG; Cole, SPC Multidrug Resistance Proteins: Role of P-Glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in Tissue Defense. Toxicol. Appl. Pharmacol. 2005, 204 (3), 216-237. Eckford, PDW; Sharom, FJABC Efflux Pump-Based Resistance to Chemotherapy Drugs. Chem. Rev. 2009, 109 (7), 2989-3011.).
[0008] They allow the transport of a wide variety of compounds and are naturally present in most cell membranes and physiological barriers in our bodies. Therefore, their physiological role in healthy humans is to defend and protect organelles and tissues from exogenous and / or xenobiotics. However, it has been shown that these ABC transporters greatly alter the absorption, distribution, metabolism and elimination of active ingredients. (Sharom, FJ ABC Multidrug Transporters: Structure, Function and Role in Chemoresistance. Pharmacogenomics 2008, 9 (1), 105-127.)
[0009] Together, these functions make these three transporters potent, novel, and prime therapeutic targets in the search for viable therapeutic solutions to suppress the problem of chemoresistance. (Bugde, P.; Biswas, R.; Merien, F.; Lu, J.; Liu, D.-X.; Chen, M.; Zhou, S.; Li, Y. The Therapeutic Potential of Targeting ABCTransporters to Combat Multi-Drug Resistance. Expert Opin. Ther. Targets 2017, 21(5), 511-530.)
[0010] Ko143 is a polycyclic organic molecule containing three asymmetric centers and is currently used as a reference inhibitor of BCRP in research. However, its optimized 5-step synthesis is cumbersome, with an overall yield of 5%, and the control of the three asymmetric centers remains a limiting parameter (Li, Y.; Hayman, E.; Plesescu, M.; Prakash, SR Synthesis of Potent BCRP Inhibitor-Ko143. Tetrahedron Lett. 2008, 49 (9), 1480-1483.)
[0011] Although the compound has good activity (50% inhibition concentration, IC50 = 0.09 μM ± 0.01), its solubility is relatively low, which affects its bioavailability. Clinical studies have shown that Ko143 is rapidly metabolized (60 minutes) by hydrolysis of its tert-butyl ester to produce an inactive metabolite. (Liu, K.; Zhu, J.; Huang, Y.; Li, C.; Lu, J.; Sachar, M.; Li, S.; Ma, X. Metabolism of KO143, an ABCG2 inhibitor. Drug Metab. Pharmacokinet. 2017, 32 (4), 193-200.) Therefore, clinical studies were stopped. Finally, the compound was initially selective for BCRP but was ultimately found to have no selectivity for ABCG2 (Weidner, LD; Zoghbi, SS; Lu, S.; Shukla, S.; Ambudkar, SV; Pike, VW; Mulder, J.; Gottesman, MM; Innis, RB; Hall, MD The Inhibitor Ko143 Is Not Specific for ABCG2. J. Pharmacol. Exp. Ther. 2015, 354(3), 384-393. Allen, JD; van Loevezijn, A.; Lakhai, JM; van der Valk, M.; van Tellingen, O.; Reid, G.; Schellens, JHM; Koomen, G.-J.; Schinkel, AH Potent and Specific Inhibition of the Breast Cancer Resistance Protein Multidrug Transporter in Vitro and in Mouse Intestine by a Novel Analogue of Fumitremorgin C.Mol.Cancer Ther.2002,1(6),417.)
[0012] The applicants have previously developed an inhibitor called MBL-II-141 that is selective, non-toxic and has good activity in preclinical models. (Honorat, M.; Guitton, J.; Gauthier, C.; Bouard, C.; Lecerf-Schmidt, F.; Peres, B.; Terreux, R.; Gervot, H.; Rioufol, C.; Boumendjel, A.; et al. MBL-II-141, a Chromone Derivative, Enhances Irinotecan(CPT-11)AnticancerEfficiency in ABCG2-Positive Xenografts.Oncotarget 2014,5(23),11957-11970.Hénin,E.;Honorat,M.;Guitton,J.;Di Pietro,A.;Payen,L.;Tod,M.PharmacokineticInteractions in Mice between Irinotecan and MBL-II-141,an ABCG2 Inhibitor:Irinotecan MBLI-II-141Interaction.Biopharm.Drug Dispos.2017. Valdameri, G.; Genoux-Bastide, E.; Peres, B.; Gauthier, C.; Guitton, J.; Terreux, R.; Winnischofer, SMB; Rocha, MEM; Boumendjel, A.; Nontoxic Inhibitors,Specific for the Breast Cancer ResistanceProtein.J.Med.Chem.2012,55(2),966-970.Lecerf-Schmidt,F.;Peres,B.;Valdameri,G.;Gauthier,C.;Winter,E.;Payen,L.;Di Pietro,A.;Boumendjel,A.ABCG2: RecentDiscovery of Potent and Highly Selective Inhibitors.Future Med.Chem.2013,5(9),1037-1045.Winter,E.;Lecerf-Schmidt,F.;Gozzi,G.;Peres,B.;Lightbody,M.;Gauthier,C.;Ozvegy-Laczka,C.;Szakacs,G.;Sarkadi,B.;Creczynski-Pasa,TB;etal.Structure-Activity Relationships of Chromone Derivatives toward the Mechanism of Interaction with and Inhibition of Breast Cancer ResistanceProtein ABCG2.J.Med.Chem.2013,56(24),9849-9860.Pires,A.do RA;Lecerf-Schmidt,F.;Guragossian,N.;Pazinato,J.;Gozzi,GJ;Winter,E.;Valdameri,G.;Veale,A.;Boumendjel,A.;Di Pietro,A.;et al.New,Highly Potent and Non-Toxic,Chromone Inhibitors of the Human Breast Cancer Resistance ProteinABCG2.Eur.J.Med.Chem.2016,122,291-301.). It has been found that the compound used as a synthetic intermediate in this latest publication is an inhibitor of breast cancer multidrug resistance protein (breast cancer resistance protein BCRP / ABCG2). .
[0013] The problem of chemoresistance is increasing due to the lack of rapidly updated anticancer agents on the market. In order to cope with the lack of new anticancer drugs, focusing one's attention on the root of the resistance problem is a feasible and economical solution. In fact, inhibiting the ability of tumor cells to protect and preserve themselves could preserve the efficacy of current anticancer drugs and limit their effective dose, which in turn limits their side effects and the overall chemotherapy costs for patients and society. In addition, it would be very interesting to find new compounds that are more effective than MBL-II-141 and Ko143. Summary of the invention
[0014] The present invention relates to a compound represented by formula (I):
[0015] [Chemical formula 1]
[0016]
[0017] or a pharmaceutically acceptable enantiomer, salt or solvate thereof, or a mixture thereof,
[0018] in:
[0019] Ring A is unsubstituted or substituted by one or two of F, Cl, Br, I, or OR at positions 2, 3, 4, or 5; wherein R = Me, Et, Pr, i-Pr, or n-Bu; O-CH2-(O-CH2CH2) n -O-CH3, wherein n=3, 4, 5, 6, and Z is
[0020] [Chemical formula 2]
[0021] or -CH2-,
[0022] Y = -OH; -OMe; -OEt; -OPr; -NH2; -NHMe; -N(Me)2; -N(Me)OCH3; -NH-(CH2)2-(3-indolyl); -NH(CH2)2-3-((5-hydroxy)indolyl); -NH-CH(R3)-COR2, wherein R2 is selected from:
[0023] -OH; -OMe; -OEt; -OPr; -NH2; -NHMe; -N(Me)2; -N(Me)OCH3; 3-(5-methoxy)indolyl; -NH-(CH2)2-(3-indolyl); -NH(CH2)2-3-((5-hydroxy)indolyl); -NH(CH2)2-3-((5-methoxy)indolyl)
[0024] [Chemical formula 3]
[0025] In formula (I), R3 of the substituent group -NH-CH(R3)-COR2 of Y is independently selected from: H or
[0026] [Chemical formula 4]
[0027]
[0028] [Chemical formula 5]
[0029]
[0030] [Chemical formula 6]
[0031]
[0032] [Chemical formula 7]
[0033]
[0034] Except for compounds having Br at the 4-position of ring A, R1=CH(CH3)2 or CH2CH(CH3)2 or CH(CH3)CH2CH3, Z=
[0035] [Chemical formula 8]
[0036] Y = -OH or -OMe.
[0037] In particular, ring A can be substituted by 1 or 2 Br at positions 2, 3, 4, or 5 and Y = -OH; -OMe; -NH-(CH2)2-(3-indolyl); -NH(CH2)2-3-((5-hydroxy)indolyl); -NH-CH(R3)-COR2, R1, R2, and R3 are as defined above.
[0038] In a specific embodiment, Y is -NH-(CH2)2-(3-indolyl) or -NH(CH2)2-3-((5-hydroxy)indolyl), provided that:
[0039] [Chemical formula 9]
[0040] yes
[0041] [Chemical formula 10]
[0042] or
[0043] [Chemical formula 11]
[0044]
[0045] In particular, the compounds according to the present invention may be selected from:
[0046] Methyl(5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-isoleucine;
[0047] Methyl(5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-leucine;
[0048] Methyl(5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-valine;
[0049] Methyl (5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-phenylalaninate;
[0050] Methyl (5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-phenylalaninate;
[0051] Methyl(5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-tryptophan;
[0052] Methyl(5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-tryptophan;
[0053] Methyl(5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-D-tryptophan;
[0054] (5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-isoleucine;
[0055] (5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-phenylalanine;
[0056] (5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-phenylalanine;
[0057] (5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-D-tryptophan;
[0058] Methyl(5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-isoleucine-L-valine;
[0059] Methyl(5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-isoleucine-L-leucine;
[0060] Methyl(5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-isoleucine-L-valine;
[0061] Methyl(5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-isoleucine-L-leucine;
[0062] (S)-5-((2-bromophenyl)oxy)-N-(1-((2-(5-hydroxy-1H-indol-3-yl)ethyl)amino)-1-oxo-3-phenylpropan-2-yl)-4-oxo-4H-chromene-2-carboxamide;
[0063] (S)-N-(1-((2-(1H-indol-3-yl)ethyl)amino)-1-oxo-3-phenylpropan-2-yl)-5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carboxamide; and
[0064] le(R)-N-(1-((2-(1H-indol-3-yl)ethyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carboxamide.
[0065] The present invention also relates to a method for obtaining the compounds according to the present invention, characterized in that it comprises the following steps:
[0066] (a) Alkyl compound represented by formula
[0067] [Chemical formula 12]
[0068] wherein ring A is as described in claim 1, X is a halogen selected from F, Cl, Br and I, and reacts with 2,6-dihydroxyacetophenone as shown in formula 13 in acetone at the reflux temperature of acetone,
[0069] [Chemical formula 13]
[0070]
[0071] The intermediate shown in formula 14 is obtained
[0072] [Chemical formula 14]
[0073]
[0074] (b) The intermediate obtained in step (a) is reacted with diethyl oxalate of formula 15 in a mixture of tetrahydrofuran (THF) / ethanol (1:1) at a temperature of 0°C-50°C
[0075] [Chemical formula 15]
[0076]
[0077] The intermediate shown in formula 16 is obtained
[0078] [Chemical formula 16]
[0079]
[0080] (c) The intermediate obtained in step (b) is reacted at 50° C. in an acidic or alkaline medium in a THF / ethanol / water solvent (3:1:1.5) by hydrolysis of the ester functional group to obtain an intermediate of formula 17
[0081] [Chemical formula 17]
[0082]
[0083] (d) The intermediate obtained in step (c) is reacted with the coupling compound shown in formula 18 in anhydrous DMF at room temperature to form an amide bond.
[0084] [Chemical formula 18]
[0085] R1, Z and Y are as defined in claim 1 to obtain a compound of formula (I).
[0086] The present invention also relates to a compound represented by formula (I):
[0087] [Chemical formula 19]
[0088]
[0089] or a pharmaceutically acceptable enantiomer, salt or solvate thereof, or a mixture thereof,
[0090] in:
[0091] Ring A is unsubstituted or substituted by one or two of F, Cl, Br, I, or OR at positions 2, 3, 4, or 5; wherein R = Me, Et, Pr, i-Pr, or n-Bu; O-CH2-(O-CH2CH2)nO-CH3, wherein n = 3, 4, 5, or 6,
[0092] Z is
[0093] [Chemical formula 20]
[0094]
[0095] or -CH2-,
[0096] Y = -OH; -OMe; -OEt; -OPr; -NH2; -NHMe; -N(Me)2; -N(Me)OCH3; -NH-(CH2)2-(3-indolyl); -NH(CH2)2-3-((5-hydroxy)indolyl); -NH-CH(R3)-COR2, wherein R2 is selected from:
[0097] -OH; -OMe; -OEt; -OPr; -NH2; -NHMe; -N(Me )2 ; -N(Me)OCH3; 3-(5-methoxy)indolyl; -NH-(CH2)2-(3-indolyl); -NH(CH2)2-3-((5-hydroxy)indolyl); -NH(CH2)2-3-((5-methoxy)indolyl)
[0098] [Chemical formula 21]
[0099] In formula (I), R3 of the substituent group -NH-CH(R3)-COR2 of Y is independently selected from: H or
[0100] [Chemical formula 22]
[0101]
[0102] [Chemical formula 23]
[0103]
[0104] [Chemical formula 24]
[0105]
[0106] [Chemical formula 25]
[0107]
[0108] Used to inhibit the multidrug resistance protein of breast cancer (breast cancer resistance protein BCRP / ABCG2).
[0109] Inhibition of breast cancer multidrug resistance protein (BCRP / ABCG2), in addition to playing a role in breast cancer treatment, may also resensitize tumor cells and enhance the pharmacokinetics and efficacy of drugs that need to cross physiological membranes or barriers (such as the blood-brain or gastrointestinal barrier) to show their therapeutic activity.
[0110] In particular, ring A can be substituted by 1 or 2 Br at positions 2, 3, 4, or 5 and Y = -OH; -OMe; -NH-(CH2)2-(3-indolyl); -NH(CH2)2-3-((5-hydroxy)indolyl); -NH-CH(R3)-COR2, R1, R2, and R3 are as defined above.
[0111] In a specific embodiment, Y is -NH-(CH2)2-(3-indolyl) or -NH(CH2)2-3-((5-hydroxy)indolyl), provided that:
[0112] [Chemical formula 26]
[0113] yes
[0114] [Chemical formula 27]
[0115] or
[0116] [Chemical formula 28]
[0117]
[0118] The compound used to inhibit the breast cancer multidrug resistance protein (breast cancer resistance protein BCRP / ABCG2) according to the present invention can be selected from:
[0119] Methyl(5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-isoleucine;
[0120] Methyl(5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-isoleucine;
[0121] Methyl(5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-leucine;
[0122] Methyl(5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-valine;
[0123] Methyl (5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-phenylalaninate;
[0124] Methyl (5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-phenylalaninate;
[0125] Methyl(5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-tryptophan;
[0126] Methyl(5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-tryptophan;
[0127] Methyl(5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-D-tryptophan;
[0128] (5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-isoleucine;
[0129] (5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-phenylalanine;
[0130] (5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-phenylalanine;
[0131] (5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-D-tryptophan;
[0132] Methyl(5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-isoleucine-L-valine;
[0133] Methyl(5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-isoleucine-L-leucine;
[0134] Methyl(5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-isoleucine-L-valine;
[0135] Methyl(5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-isoleucine-L-leucine;
[0136] (S)-5-((2-bromophenyl)oxy)-N-(1-((2-(5-hydroxy-1H-indol-3-yl)ethyl)amino)-1-oxo-3-phenylpropan-2-yl)-4-oxo-4H-chromene-2-carboxamide;
[0137] (S)-N-(1-((2-(1H-indol-3-yl)ethyl)amino)-1-oxo-3-phenylpropan-2-yl)-5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carboxamide, and
[0138] (R)-N-(1-((2-(1H-indol-3-yl)ethyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-5-((4-bromophenoxy)oxy)-4-oxo-4H-chromene-2-carboxamide.
[0139] The present invention also relates to a pharmaceutical composition comprising:
[0140] at least one pharmaceutically acceptable active agent; and
[0141] At least one compound as defined above.
[0142] Specifically, the pharmaceutically acceptable active agent may be selected from anticancer agents, intestinal anti-inflammatory agents, hypocholesterolemic agents, anti-dyslipidemic agents and kinase inhibitors.
[0143] For example, sulfosalicylic acid can be used as an intestinal anti-inflammatory agent, atorvastatin can be used as a hypocholesterolemic agent, rosuvastatin can be used as an antilipidemic agent, and imatinib mesylate can be used as an anticancer agent or a kinase inhibitor.
[0144] These compounds, which can be distinguished by the presence of a natural amino acid or an enantiomer of a natural amino acid attached to a chromone unit, were synthesized in four steps from commercial 2,6-dihydroxyacetophenone 1 (Scheme 1) with overall yields ranging from 13% to 41%. Intermediate 2 was obtained in three standard steps: alkylation, Kostaneki reaction and saponification with an overall yield of 45%. For example, when a natural amino acid or an enantiomer of a natural amino acid is attached to a chromone unit, the last step is carried out by a coupling reaction, for example by peptide coupling, with the assistance of a coupling agent that promotes the reaction and limits the number of equivalents of the reactants.
[0145] These reagents are inexpensive and commonly used in laboratories. In addition, these reactions are not too energy-intensive and the purification of the products by precipitation or recrystallization limits the volume of organic solvents used and, therefore, the volume of waste. Finally, the compounds are isolated in pure form and their structures are determined and verified by various analytical techniques (NMR, mass spectrometry, X-ray diffraction). It should be noted that X-ray diffraction confirms the absence of racemization of the asymmetric centers of commercial amino acids.
[0146] Scheme 1: Synthetic pathway of the BCRP inhibitors of the present invention.
[0147] [Chemical formula 29]
[0148]
[0149] The following examples illustrate the invention without limiting its scope.
[0150] In these embodiments:
[0151] NMR spectra were recorded on a Bruker Avance-400 400 MHz instrument (400 MHz) or a Bruker Avance-500 500 MHz instrument (500 MHz).
[0152] Chemical shifts (δ) are reported in ppm relative to Me4Si used as an internal standard.
[0153] Electrospray ionization (ESI) mass spectra were acquired by the Analytical Department of the University of Grenoble on a Waters Xevo G2-S Q-TOF instrument with nanospray input. Exact masses are reported in m / z.
[0154] HPLC analysis was performed using an Agilent 1100 series system with a diode array detector and a C18 reverse phase column (Nucleosil C18, Macherey-Nagel, 5 mm particle size, 125 mm x 3 mm) at 45 °C, using a mobile phase consisting of A: water and 0.1% trifluoroacetic acid (TFA) and B: methanol (MeOH) and 0.1% TFA, under the conditions of 14 min, 1 mL / min, 10 μL injection, detection at 254 nm, and an A:B gradient between 85:15 and 0:100.
[0155] Melting points (mp) in degrees Celsius (° C.) were obtained on a Büchi B540 melting point scale.
[0156] Thin layer chromatography (TLC) was performed on Merck F-254 silica gel plates (0.25 mm thick).
[0157] Unless otherwise noted, reagents were obtained from commercial sources (Alpha Aesar, Sigma Aldrich, and TCI) and used without further purification. DETAILED DESCRIPTION
[0158] Examples 1 to 20
[0159] Series 1
[0160] [Chemical formula 30]
[0161]
[0162] NOTE: In the following protocol, "molecule number + a" refers to when the bromine is located at position 2 of the aromatic ring, and "molecule number + b" refers to when the bromine is located at position 4 of the aromatic ring.
[0163] General Procedure A:
[0164] To a solution of 2,6-dihydroxyacetophenone 1 (1 eq.) in acetone (6 mL / mmol) were added K2CO3 (3 eq.) and tetra-n-butylammonium bromide (0.4 eq.) which had been homogenized together previously.
[0165] The solution was refluxed for 30-60 minutes, and then the corresponding bromobenzene bromide (1 equiv.) was added dropwise in acetone (15 mL / mmol).
[0166] The solution was then refluxed for 4-5 hours and monitored by TLC (ethyl acetate / cyclohexane 3:7). The solution was poured into water and extracted with ethyl acetate. The organic phase was collected and rinsed with water and brine, then dried over magnesium sulfate, filtered and evaporated under vacuum.
[0167] General Procedure B:
[0168] To a solution of 2 (1 eq.) in anhydrous tetrahydrofuran (10 mL / mmol) was added a sodium glycolate solution generated in situ from sodium (6 eq.) in anhydrous ethanol (15 mL / mmol) at 0 °C under an inert atmosphere.
[0169] The solution was stirred at room temperature for 30 minutes, and diethyl oxalate (4 equivalents) was added dropwise to the solution. The solution was then heated to 50°C until precipitation, and then refluxed for 2 hours. The reaction was monitored by TLC (cyclohexane / ethyl acetate 1:1).
[0170] A few drops of concentrated hydrochloric acid (37%) were then added to the solution until the formed precipitate turned white.
[0171] The solution was refluxed for 1 hour and then cooled to room temperature. After vacuum concentration, the solution was poured into water and extracted with ethyl acetate. The organic phase was collected and rinsed with water and brine, then dried over magnesium sulfate, filtered and evaporated under vacuum.
[0172] General operating procedure C:
[0173] To a solution of 3 (1 eq.) in THF (25 mL / mmol) and ethanol (8 mL / mmol) was added K2CO3 (1.3 eq.) in water (12 mL / mmol).
[0174] The solution was heated to 50°C for 4 hours and monitored by TLC (ethyl acetate / cyclohexane 1:1). The solution was concentrated under vacuum and then poured into alkaline water (K2CO3 20%) and washed with ethyl acetate. The alkaline aqueous phase was acidified with concentrated hydrochloric acid (37%) and extracted with ethyl acetate.
[0175] The organic phases were then collected, washed with water and brine, then dried over magnesium sulfate, filtered and evaporated.
[0176] General operating procedures D:
[0177] To a solution of the carboxylic acid derivative 4 (1 eq.) in anhydrous dimethylformamide (DMF) (20 mL / mmol) was added 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylammonium tetrafluoroborate (TBTU) (2 eq.) The solution was stirred at room temperature for 30 minutes.
[0178] Next, a solution of the amino acid derivative (2 eq.) in DMF (10 mL / mmol) containing N,N-diisopropylethylamine (DIEA) (4 eq.) was carefully added to the previous solution. The reaction was stirred at room temperature for 12 or 24 h and monitored by TLC (ethyl acetate / cyclohexane 1:1). The solution was concentrated under vacuum, then poured into acidified water (1 M HCl) and extracted with ethyl acetate.
[0179] The organic phases were collected and washed with NaHCO3 solution (20%), water and brine, then dried over magnesium sulfate, filtered and concentrated under vacuum.
[0180] General operation mode E:
[0181] To a solution of ester derivative 5 (1 eq.) in THF (25 mL / mmol) and methanol (10 mL / mmol) was added a solution of LiOH (1.5 eq.) in H2O (10 mL / mmol). The reaction was stirred at room temperature for 2 h and monitored by TLC (ethyl acetate / cyclohexane 1:1).
[0182] The solution was poured into alkaline water (20% NaHCO3) and washed with ethyl acetate. The aqueous phase was acidified with concentrated hydrochloric acid (37%) and extracted with ethyl acetate.
[0183] The organic phase was then collected and washed with brine, then dried over magnesium sulfate, filtered and concentrated under vacuum.
[0184] Example 1
[0185] Preparation of 1-(2-((2-bromophenyl)oxy)-6-hydroxyphenyl)ethan-1-one (2a)
[0186] [Chemical formula 31]
[0187]
[0188] The crude product was prepared according to General Procedure A starting from 1 (1.500 g, 9.86 mmol) and purified by recrystallization from methanol or ethyl acetate to afford 2a (2.583 g, 82%). 15 H 13 BrO3.
[0189] 1 H NMR (400MHz, DMSO) δ11.69(s,1H),7.71(dd,J=8.0,1.1Hz,1H),7.61(dd,J=7.6,1.6Hz,1H),7.46(td,J=7.5,1, 2Hz, 1H), 7.39-7.29 (m, 2H), 6.67 (dd, J=8.4, 0.5Hz, 1H), 6.56 (dd, J=8.3, 0.7Hz, 1H), 5.19 (s, 2H), 2.47 (s, 3H).
[0190] 13C NMR (101MHz, DMSO) δ203.38,159.60,157.95,135.31,133.90,132.72,130.64,130.41,128.00,123.04,114.62,109.83,103.19,70.02,32.86
[0191] mp:75.5-77.4℃.
[0192] MS (ESI) m / z 321( 79 Br),323( 81 Br)[M+H] + ,319( 79 Br),321( 81 Br)[MH] + .
[0193] Example 2
[0194] Preparation of 1-(2-((4-bromophenyl)oxy)-6-hydroxyphenyl)ethan-1-one (2b)
[0195] [Chemical formula 32]
[0196]
[0197] The crude product was prepared according to General Procedure A starting from 1 (1.500 g, 9.86 mmol) and purified by recrystallization in ethyl acetate to afford 2b (2.321, 73%). 15 H 13 BrO3.
[0198] 1 H NMR (400MHz, DMSO) δ11.64(s,1H),7.62-7.58(m,2H),7.45-7.41(m,2H),7.30(t,J=8.3H z,1H),6.62(dd,J=8.4,0.5Hz,1H),6.52(dd,J=8.3,0.7Hz,1H),5.14(s,2H),2.48(s,3H)
[0199] 13 C NMR (101MHz, DMSO) δ203.43,159.52,157.94,135.96,133.77,131.41,129.98,121.15,114.75,109.63,103.41,69.30,33.04
[0200] mp:114.8-116.8℃.
[0201] MS (ESI) m / z 320 ( 79 Br),322( 81 Br)[M] + .
[0202] Example 3
[0203] Preparation of ethyl 5-((2-bromophenyl)oxy)-4-oxy-4H-chromene-2-carboxylate (3a)
[0204] [Chemical formula 33]
[0205]
[0206] The crude product was prepared according to General Procedure B starting from 2a (2.583 g, 8.04 mmol) and purified by recrystallization from methanol or ethyl acetate to afford 3a (2.478, 76%). 19 H 15 BrO5.
[0207] 1 H NMR (400MHz, DMSO) δ8.11(dd,J=7.7,1.4Hz,1H),7.79(t,J=8.4Hz,1H),7.68(dd,J=8.0,1.0Hz,1H),7.51(td,J=7.6,1.1Hz,1H),7,3 3(td,J=7.8,1.7Hz,1H),7.30-7.25(m,1H),7.18-7.13(m,1H),6.79(s,1H),5.23(s,2H),4.40(q,J=7.1Hz,2H),1.36(t,J=7.1Hz,3H)
[0208] 13 C NMR(101MHz,DMSO)δ176.40,172.49,160.01,158.25,157.43,150.24,135.70,135.44,132 .17,129.57,129.12,127.85,121.05,115.43,114.62,110.78,108.85,69.72,62.61,13.87
[0209] mp:155.3-157.1℃.
[0210] MS (ESI) m / z 403 ( 79 Br),405( 81 Br)[MH] + .
[0211] Example 4
[0212] Preparation of ethyl 5-((4-bromophenyl)oxy)-4-oxy-4H-chromene-2-carboxylic acid (3b)
[0213] [Chemical formula 34]
[0214]
[0215] The crude product was prepared according to General Procedure B starting from 2b (1.718 g, 5.35 mmol) and purified by recrystallization from methanol or ethyl acetate to afford 3b (1.516, 70%). 19 H 15 BrO5.
[0216] 1 H NMR (400MHz, DMSO) δ7.74 (t, J = 8.4Hz, 1H), 7.64-7.56 (m, 4H), 7.25-7.21 (m, 1H), 7.13 -7.08(m,1H),6.77(s,1H),5.24(s,2H),4.38(q,J=7.1Hz,2H),1.34(t,J=7.1Hz,3H).
[0217] 13 C NMR(101MHz,DMSO)δ176.39,160.01,157.70,157.23,150.19,136.23,135.29, 131.21,128.90,120.61,115.43,114.68,110.54,109.02,69.22,62.59,13.87
[0218] mp:148.0-149.4℃.
[0219] MS (ESI) m / z 402 ( 79 Br),404( 81 Br)[M]+.
[0220] Example 5
[0221] Preparation of 5-((2-bromophenyl)oxy)-4-oxy-4H-chromene-2-carboxylic acid (4a)
[0222] [Chemical formula 35]
[0223]
[0224] The crude product was prepared starting from 3a (1.000 g, 2.48 mmol) according to General Procedure C and purified by trituration in methanol and washing with ether to give 4a (0.777, 84%). The desired product was also obtained by crystallization from methanol.17 H 11 BrO5.
[0225] 1 H NMR (400MHz, DMSO) δ8.14(dd,J=7.7,1.1Hz,1H),7.77(t,J=8.4Hz,1H),7.68(dd,J=8.0,0.9Hz,1H),7.51(td,J=7, 6,0.9Hz,1H),7.32(td,J=7.8,1.5Hz,1H),7.26(d,J=8.1Hz,1H),7.13(d,J=8.3Hz,1H),6.74(s,1H),5.23(s,2H).
[0226] 13 C NMR(101MHz,DMSO)δ176.70,161.44,157.42,157.36,151.31,135.75,135.24,1 32.13,129.52,129.13,127.82,121.01,115.17,114.63,110.80,108.71,69.71
[0227] mp:244.3℃.
[0228] MS (ESI) m / z 373 ( 79 Br),375( 81 Br)[MH]-.
[0229] Example 6
[0230] Preparation of 5-((4-bromophenyl)oxy)-4-oxy-4H-chromene-2-carboxylic acid (4b)
[0231] [Chemical formula 36]
[0232]
[0233] The crude product was prepared according to General Procedure C starting from 3b (1.586 g, 3.93 mmol) and purified by trituration in methanol and washing with ether to give 4b (1.259, 85%). The desired product could be crystallized in methanol to give white crystals. 17 H 11 BrO5.
[0234] 1H NMR (400MHz, DMSO) δ7.76(t,J=8.4Hz,1H),7.66-7.59(m,4H),7.24(dd,J=8.4,0.7Hz,1H),7.14-7.10(m,1H),6.76(s,1H),5.27(s,2H)
[0235] 13 C NMR (101MHz, DMSO) δ176.69,161.44,157.69,157.35,151.15,136.27,135.14,131.20,128.89,120.58,115.21,114.69,110.58,108.93,69.23
[0236] mp:204.6-205.3℃.
[0237] MS (ESI) m / z 374 ( 79 Br),376( 81 Br)[M] + .
[0238] Example 7
[0239] Preparation of methyl (5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-isoleucine (5a) Preparation
[0240] [Chemical formula 37]
[0241]
[0242] The crude product was prepared according to General Procedure D starting from 4a (511 mg, 1.36 mmol) and isoleucine methyl ester hydrochloride (0.485 g, 2.72 mmol) and purified by recrystallization in methanol to afford 5a (0.352 g, 51%). 24 H 24 BrNO6.
[0243] 1H NMR(400MHz,DMSO)δ9.23(d,J=7.7Hz,1H),8.14(d,J=7.4Hz,1H),7.82(t,J=8.4Hz,1H), 7.69(d,J=7.9Hz,1H),7.52(t,J=7.4Hz,1H),7.40(d,J=8.4Hz,1H),7.33(t,J=7.3Hz,1H ),7.17(d,J=8.3Hz,1H),6.74(s,1H),5.25(s,2H),4.39(t,J=7.7Hz,1H),3.70(s,3H),2 .10-1.99(m,1H),1.60-1.48(m,J=11.6,5.8Hz,1H),1.33-1.23(m,1H),0.97-0.86(m,6H)
[0244] 13 C NMR (101MHz, DMSO) δ176.44,171.41,159.61,157.38,157.05,152.97,135.76,135.11,132.17,129.56,1 29.14,127.85,121.04,114.49,112.75,111.09,108.81,69.70,57.26,51.90,35.48,25.09,15.37,10.77
[0245] mp:123.1-125.7℃.
[0246] HRMS(ESI / QTOF):
[0247] Calculate C 24 H 25 BrNO6(M+H + ):502.0865,
[0248] Found: 502.0860.
[0249] Purity (HPLC) >95%.
[0250] Example 8
[0251] Preparation of methyl (5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-isoleucine (5b) Preparation
[0252] [Chemical formula 38]
[0253]
[0254] The crude product was prepared according to General Procedure D starting from 4b (300 mg, 0.80 mmol) and L-isoleucine methyl ester hydrochloride (290 mg, 1.60 mmol) and purified by recrystallization in methanol to give 5b (318 mg, 79%). 24 H 24 BrNO6.
[0255] 1H NMR (400MHz, DMSO) δ9.17(d,J=7.9Hz,1H),7.77(t,J=8.4Hz,1H),7.64-7.56(m,4H),7.34(dd,J=8.5,0.7Hz,1H),7.12(d,J=8.1Hz,1H), 6.70(s,1H),5.25(s,2H),4.37(t,J=7.7Hz,1H),3.68(s,3H),2.07-1.96(m,1H),1.58-1.45(m,1H),1.32-1.19(m,1H),0.95-0.84(m,6H)
[0256] 13 C NMR(101MHz,DMSO)δ176.41,171.40,159.62,157.63,157.04,152.91,136.29,134.95,131.21,1 28.92,120.59,114.54,112.73,110.86,108.99,69.19,57.24,51.88,35.48,25.09,15.37,10.77
[0257] Example 9
[0258] Preparation of methyl (5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-leucine (5c)
[0259] [Chemical formula 39]
[0260]
[0261] The crude product was prepared according to General Procedure D starting from 4a (500 mg, 1.33 mmol) and L-leucine methyl ester hydrochloride (0.483 g, 2.66 mmol) and purified by recrystallization in methanol to afford 5c (234 mg, 35%). 24 H 24 BrNO6.
[0262] 1H NMR (400MHz, CDCl3) δ8.13(d,J=7.4Hz,1H),7.57(t,J=8.3Hz,1H),7.48(d,J=7.9Hz,1H),7.38(t,J=7.5Hz,1H),7.18-7,05(m ,3H),6.98(s,1H),6.90(d,J=8.3Hz,1H),5.18(s,2H),4.82-4.73(m,1H),3.74(s,3H),1.80-1.60(m,3H),0.99-0.87(m,6H).
[0263] 13 C NMR (101MHz, CDCl3) δ177.52,172.93,159.05,158.46,157.33,152.34,135.55,134.74,132.10,129.07,1 28.79,128.12,120.82,115.42,114.21,110.63,108.66,70.38,52.73,51.14,41.81,25.02,22.82,22.05
[0264] mp:60.3-60.4℃.
[0265] HRMS (ESI / QTOF):
[0266] Calculate C 24 H 25 BrNO6(M+H + ):502.0865,
[0267] Found: 502.0865.
[0268] Purity (HPLC)>98%.
[0269] Example 10
[0270] Preparation of methyl (5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-valine (5d)
[0271] [Chemical formula 40]
[0272]
[0273] The crude product was prepared according to General Procedure D starting from 4a (0.200 g, 0.53 mmol) and L-valine methyl ester hydrochloride (0.179 g, 1.07 mmol) and purified by recrystallization in methanol to give 5d (0.126 g, 48%). 23 H 22 BrNO6.
[0274] 1 H NMR (400MHz, DMSO) δ9.20(d,J=7.8Hz,1H),8.12(d,J=7.4Hz,1H),7.82(t,J=8.4Hz,1H),7.69(d,J=7.8Hz,1H),7.51(t,J=7.5Hz,1H),7.39(d,J=8.4Hz ,1H),7.33(t,J=7.4Hz,1H),7.16(d,J=8.3Hz,1H),6.74(s,1H),5.24(s,2H ),4.33(t,J=7.7Hz,1H),3.70(s,3H),2.32-2.19(m,1H),1.06-0.92(m,6H)
[0275] 13 C NMR (101MHz, DMSO) δ176.42,171.34,159.69,157.41,157.07,153.03,135.76,135.09,132.17,129.5 7,129.18,127.84,121.07,114.53,112.74,111.10,108.88,69.76,58.56,51.90,29.46,19.04,18.95
[0276] mp:127.0-128.2℃.
[0277] HRMS(ESI / QTOF):
[0278] Calculate C 23 H 23 BrNO6(M+H + ): 488.0709,
[0279] Found: 488.0719.
[0280] Purity (HPLC)>98%.
[0281] Embodiment 11
[0282] Methyl (5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-phenylalanine methyl ester (5e) Preparation
[0283] [Chemical formula 41]
[0284]
[0285] The crude product was prepared according to General Procedure D starting from 4a (0.194 g, 0.52 mmol) and L-phenylalanine methyl ester hydrochloride (0.223 g, 1.04 mmol) and purified by precipitation in diethyl ether and cyclohexane to give 5e (0.187 g, 70%). 27 H 22 BrNO6.
[0286] 1 H NMR (400MHz, DMSO) δ9.47 (s, 1H), 8.13 (dd, J = 7.7, 1.5Hz, 1H), 7.82 (t, J = 8.4H z,1H),7.68(dd,J=8.0,1.1Hz,1H),7.51(td,J=7.6,1.1Hz,1H),7.35-7.27(m ,6H),7.25-7.19(m,1H),7.16(d,J=8.0Hz,1H),6.64(s,1H),5.24(s,2H),4.7 7-4.71(m,1H),3.69(s,3H),3.26(dd,J=13.8,5.4Hz,1H),3.21-3.13(m,1H).
[0287] 13 C NMR (101MHz, DMSO) δ176.33,171.26,159.21,157.42,156.95,152.77,137.22,135.74,135.24,132.15,129.54,12 9.11,129.06,128.31,127.84,126.62,121.01,114.43,112.57,110.82,108.85,69.69,54.13,52.20,35.93,30.67
[0288] mp:145.5-147.5℃.
[0289] HRMS(ESI / QTOF):
[0290] Calculate C 27 H 23 BrNO6(M+H + ): 536.0709,
[0291] Found: 536.0711.
[0292] Purity (HPLC) >97%.
[0293] Example 12
[0294] Methyl (5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-phenylalanine methyl ester (5f) Preparation
[0295] [Chemical formula 42]
[0296]
[0297] The crude product was prepared according to General Procedure D starting from 4b (0.472 g, 1.26 mmol) and L-phenylalanine methyl ester hydrochloride (0.453 g, 2.52 mmol) and purified by recrystallization in methanol to afford 5f (0.551 g, 90%). 27 H 22 BrNO6.
[0298] 1 H NMR (400MHz, DMSO) δ9.43(d,J=7.9Hz,1H),7.79(t,J=8.4Hz,1H),7.68-7.54(m,4H),7.30(d,J=12.6Hz,5H),7.23(d,J=6.1Hz,1H),7.13(d,J= 8.3Hz,1H),6.63(s,1H),5.26(s,2H),4.73(dd,J=13.5,9.1Hz,1H),3.68(s,3H),3.26(dd,J=13.8,5.2Hz,1H),3.16(dd,J=13.6,10.3Hz,1H).
[0299] 13 C NMR (101MHz, DMSO) δ176.31,171.22,159.22,157.68,156.94,152.71,137.20,136.26,135.08,131.20 ,129.05,128.91,128.31,126.62,120.59,114.50,112.56,110.60,109.06,69.21,54.10,52.20,35.93
[0300] Decomposition point: 153.1℃.
[0301] HRMS (ESI / QTOF):
[0302] Calculate C 27 H 23 BrNO6(M+H + ): 536.0709,
[0303] Found: 536.0704.
[0304] Purity (HPLC) >96%.
[0305] Example 13
[0306] Methyl (5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-tryptophanate (5 g) preparation
[0307] [Chemical formula 43]
[0308]
[0309] The crude product was prepared according to General Procedure D starting from 4a (0.100 g, 0.27 mmol) and L-tryptophan methyl ester hydrochloride (0.136 g, 0.53 mmol) and purified by recrystallization in methanol to afford 5 g (0.043 g, 28%). 29 H 23 BrN2O6.
[0310] 1 H NMR (400MHz, DMSO) δ10.89(s,2H),9.36(d,J=7.8Hz,2H),8.12(d,J=7.7Hz,2H),7.83(t, J=8.4Hz,2H),7.69(dd,J=8.0,0.9Hz,2H),7.62(d,J=7.8Hz,2H),7.51(td,J=7.5,0.9Hz, 2H),7.39-7.28(m,6H),7.25(d,J=2.2Hz,2H),7.17(d,J=8.3Hz,2H),7.07(td,J=7.7,0. 9Hz,2H),6.98(t,J=7.4Hz,2H),6.65(s,2H),5.24(s,4H),4.80-4.70(m,2H),3.69(s,7H)
[0311] 13 C NMR (101 MHz, DMSO) δ 176.36, 171.52, 159.18, 157.43, 156.95, 152.81, 136.09, 135.74, 135.21, 132.17, 129.57, 129.15, 127.85, 127.03, 123.79, 121.05, 121.02, 118.44, 118.04, 114.43, 112.55, 111.48, 110.83, 109.47, 108.89, 69.73, 53.80, 52.19, 26.38. There are two proton signals below the water peak.
[0312] mp:250-252.8℃.
[0313] HRMS (ESI / QTOF):
[0314] Calculate C 29 H 24 BrN2O6(M+H + ):575.0818,
[0315] Found: 575.0821.
[0316] Purity (HPLC) >99%.
[0317] Embodiment 14
[0318] Methyl (5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-tryptophanate (5h) preparation
[0319] [Chemical formula 44]
[0320]
[0321] The crude product was prepared according to General Procedure D starting from 4b (0.100 g, 0.27 mmol) and L-tryptophan methyl ester hydrochloride (0.136 g, 0.533 mmol) and purified by recrystallization in methanol to give 5h (0.126 g, 82%). 29 H 23 BrN2O6.
[0322] 1 H NMR (400MHz, DMSO) δ10.90(s,1H),9.34(d,J=7.8Hz,1H),7.79(t,J=8.4Hz,1H),7.69-7.52(m,5H),7.35(d,J=8.1Hz,1H),7.29(d,J=8.1Hz,1H )7.25(d,J=2.2Hz,1H),7.12(d,J=8.3Hz,1H),7.10-7.03(m,1H),7.02 -6.94(m,1H),6.63(s,1H),5.25(s,2H),4.80-4.69(m,1H),3.68(s,3H)
[0323] 13C NMR (101 MHz, DMSO) δ 176.34, 171.50, 159.19, 157.67, 156.92, 152.76, 136.25, 136.10, 135.04, 131.20, 128.92, 127.03, 123.78, 121.02, 120.59, 118.44, 118.04, 114.48, 112.54, 111.48, 110.61, 109.47, 109.06, 69.23, 53.79, 52.18, 26.39, two proton signals under the water peak.
[0324] mp:235.3-236.2℃.
[0325] HRMS(ESI / QTOF):
[0326] Calculate C 29 H 24 BrN2O6(M+H + ):575.0818,
[0327] Found: 575.0807.
[0328] Purity (HPLC) >99%.
[0329] Embodiment 15
[0330] Methyl (5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-D-tryptophanate (5i) preparation
[0331] [Chemical formula 45]
[0332]
[0333] The crude product was prepared according to General Procedure D starting from 4b (0.300 g, 0.80 mmol) and D-tryptophan methyl ester hydrochloride (0.408 g, 1.60 mmol) and purified by precipitation in ethyl acetate and cyclohexane to give 5i (0.375 g, 81%). 29 H 23 BrN2O6.
[0334] 1H NMR (400MHz, DMSO) δ10.90 (s, 1H), 9.34 (d, J = 7.8Hz, 1H), 7.79 (t, J = 8.4Hz, 1H), 7. 66-7.57(m,5H),7.35(d,J=8.1Hz,1H),7.29(d,J=8.3Hz,1H),7.25(d,J=2.1Hz,1H )7.12(d,J=8.3Hz,1H),7.07(t,J=7.2Hz,1H),6.98(t,J=7.4Hz,1H),6.63(s,1H), 5.25(s,2H),4.79-4.70(m,1H),3.69(s,3H),3.43-3.38(m,1H),3.33-3.27(m,1H)
[0335] 13 C NMR (101MHz, DMSO) δ176.33,171.51,159.18,157.67,156.93,152.75,136.26,136.10,135.04,131.20,128.91,127.03 ,123.78,121.01,120.59,118.43,118.04,114.48,112.54,111.48,110.60,109.47,109.04,69.21,53.79,52.18,26.38
[0336] mp:236.2-237.9℃.
[0337] HRMS(ESI / QTOF):
[0338] Calculate C 29 H 24 BrN2O6(M+H + ):575.0818,
[0339] Found: 575.0822.
[0340] Purity (HPLC)>99%.
[0341] Example 16
[0342] Preparation of (5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-isoleucine (6a)
[0343] [Chemical formula 46]
[0344]
[0345] The crude product was prepared according to General Procedure E starting from 5a (0.256 g, 0.51 mmol) and purified by recrystallization in methanol to afford 6a (0.114 g, 46%). 23 H 22 BrNO6.
[0346] 1 H NMR (400MHz, DMSO) δ8.99(d,J=8.1Hz,1H),8.14(d,J=7.5Hz,1H),7.82(t,J=8.4Hz,1H),7,6 9(dd,J=7.9,0.8Hz,1H),7.52(td,J=7.6,0.8Hz,1H),7.41(d,J=8.2Hz,1H),7.33(td,J=7.8 ,1.5Hz,1H),7.17(d,J=8.2Hz,1H),6.73(s,1H),5.25(s,2H),4.39-4.31(m,1H),2.08-1.98 (m,1H),1.61-1.48(m,1H),1.35-1.23(m,1H),0.97(d,J=6.8Hz,3H),0.90(t,J=7.4Hz,3H).
[0347] 13 C NMR (101MHz, DMSO) δ176.46,172.23,159.43,157.39,157.06,153.18,135.76,135.07,132.16,129.5 7,129.16,127.84,121.06,114.49,112.64,111.12,108.84,69.73,57.21,35.62,25.04,15.52,10.96
[0348] mp:242.8-243.7℃.
[0349] HRMS(ESI / QTOF):
[0350] Calculate C 23 H 23 BrNO6(M+H + ): 488.0709,
[0351] Found: 488.0712.
[0352] Purity (HPLC)>98%.
[0353] Embodiment 17
[0354] Preparation of (5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonyl)-L-isoleucine (6b)
[0355] [Chemical formula 47]
[0356]
[0357] The crude product was prepared according to General Procedure E starting from 5b (671 mg, 0.51 mmol) and obtained by recrystallization from methanol to give 6b (419 mg, 64%). 23 H 22 BrNO6.
[0358] 1 H NMR (400MHz, DMSO) δ12.91(s,1H),8.98(d,J=8.1Hz,1H),7.78(t,J=8.4Hz,1 H),7.67-7.57(m,4H),7.37(dd,J=8.5,0.6Hz,1H),7.13(d,J=8.2Hz,1H)6.72 (s,1H),5.26(s,2H),4.40-4.29(m,1H),2.07-1.96(m,1H),1.61-1.45(m,1H ),1.38-1.20(m,1H),0.96(d,J=6.8Hz,3H),0.90(t,J=7.4Hz,3H).(ERO1-94)
[0359] 13 C NMR(101MHz,DMSO)δ176.44,172.23,159.44,157.63,157.04,153.12,136.28,134.91,131.2 0,128.93,120.59,114.54,112.63,110.89,108.99,69.21,57.19,35.63,25.04,15.52,10.96
[0360] pf:230,1-230,4℃.
[0361] HRMS(ESI / QTOF):
[0362] Calculate C 23 H 23 BrNO6(M+H + ): 488.0709,
[0363] Found: 488.0715.
[0364] Purity (HPLC)>98%.
[0365] Embodiment 18
[0366] Preparation of (5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-phenylalanine (6c)
[0367] [Chemical formula 48]
[0368]
[0369] The crude product was prepared according to General Procedure E starting from 5e (0.320 g, 0.60 mmol) and purified by recrystallization in methanol to afford 6c (0.210 g, 67%). 26 H 20 BrNO6.
[0370] 1 H NMR (400 MHz, DMSO) δ 9.29 (d, J = 8.2 Hz, 2H), 8.11 (dd, J = 7.6, 1.0 Hz, 2H), 7.82 (t, J = 8.4 Hz, 2H), 7.68 (dd, J = 7.9, 0.8 Hz, 2H), 7.50 (td, J = 7.6, 0.9 Hz, 2H), 7.37-7.25 (m, 11H), 7.24-7.10 (m, 4H), 6.63 (s, 2H), 5.23 (s, 4H), 4.72-4.58 (m, 2H), 3.14 (dd, J = 13.8, 10.3 Hz, 5H) a peak under the water signal.
[0371] 13 C NMR (101MHz, DMSO) δ176.37,172.20,159.04,157.44,156.96,153.00,137.72,135.73,135.20,132.16,129 .57,129.17,129.02,128.25,127.83,126.47,121.06,114.45,112.43,110.85,108.91,69.75,54.18,36.01
[0372] pf:240.4-241.7℃.
[0373] HRMS(ESI / QTOF):
[0374] Calculate C 26 H 21 BrNO6(M+H + ): 522.0552,
[0375] Found: 522.0558
[0376] Embodiment 19
[0377] Preparation of (5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-phenylalanine (6d)
[0378] [Chemical formula 49]
[0379]
[0380] The crude product was prepared according to General Procedure E starting from 5f (0.551 g, 1.03 mmol) and purified by recrystallization in methanol to afford 6d (0.446 g, 83%). 26 H 20 BrNO6.
[0381] 1 H NMR (400MHz, DMSO) δ8.51(d,J=6.8Hz,1H),7.72(t,J=8.4Hz,1H),7.66-7.57(m,4H),7.24-7.16(m,5H),7.16-7,07(m,2H),6 .62(s,1H),5.24(s,2H),4.24(dd,J=11.0,5.9Hz,1H),3.26(dd,J=13.5,4.6Hz,1H),3.11(dd,J=13.5,6.8Hz,1H)(ERO1-71)
[0382] 13 C NMR (101MHz, DMSO) δ176.35,172.19,159.11,157.67,156.94,152.89,137.66,136.26,135.06,131 .20,129.02,128.91,128.27,126.50,120.58,114.47,112.44,110.62,109.04,69.21,54.08,35.94
[0383] Decomposition point: 231.5℃.
[0384] HRMS(ESI / QTOF):
[0385] Calculate C 26 H 21 BrNO6(M+H + ):522.0552,
[0386] Found: 522.0559.
[0387] Purity (HPLC) >95%.
[0388] Embodiment 20
[0389] Preparation of (5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-D-tryptophan (6e)
[0390] [Chemical formula 50]
[0391]
[0392] The crude product was prepared according to General Procedure E starting from 5i (0.250 g, 0.27 mmol) and purified by precipitation in ethyl acetate and cyclohexane to afford 6e (0.158 g, 66%). 28 H 21 BrN2O6.
[0393] 1 H NMR (400 MHz, DMSO) δ 10.87 (d, J = 1.4 Hz, 1H), 9.18 (d, J = 8.1 Hz, 1H), 7.79 (t, J = 8.4 Hz, 1H), 7.69-7.56 (m, 5H), 7.34 (d, J = 8.1 Hz, 1H) J = 8.2 Hz, 1H), 7.24 (d, J = 2.2 Hz, 1H), 7.13 (d, J = 8.3 Hz, 1H), 7.10-7.04 (m, 1H), 7.01-6.95 (m, 1H), 6.63 (s, 1H), 5.25 (s, 2H), 4.73-4.65 (m, 1H) two signals under the water peak.
[0394] 13 C NMR (101 MHz, DMSO) δ 176.37, 172.52, 159.06, 157.66, 156.92, 152.92, 136.26, 136.08, 135.04, 131.20, 128.91, 127.09, 123.66, 120.98, 120.58, 118.39, 118.16, 114.44, 112.42, 111.43, 110.59, 109.93, 109.00, 69.18, 53.73, 26.37. Two proton signals under the water peak.
[0395] mp:185.5-186.7℃.
[0396] HRMS(ESI / QTOF):
[0397] Calculate C 28 H 22 BrN2O6(M+H + ):561.0661,
[0398] Found: 561.0672.
[0399] Purity (HPLC) >99%.
[0400] Examples 21-27
[0401] Series 2
[0402] [Chemical formula 51]
[0403]
[0404] NOTE: In the following protocol, "molecule number + a" refers to when the bromine is located at position 2 of the aromatic ring, and "molecule number + b" refers to when the bromine is located at position 4 of the aromatic ring.
[0405] Note: Same synthetic scheme as Series 1 up to step e. Only step f which allows access to compound 7 is different.
[0406] General operating procedures F:
[0407] To a solution of carboxylic acid derivative 6 (1 equivalent) in anhydrous DMF (20 mL / mmol) was added TBTU (1.5 equivalent or 2 equivalent). The solution was stirred at room temperature for 30 minutes. Therefore, a solution of amino acid derivative (1.5 or 2 equivalent) in DMF (10 mL / mmol) containing DIEA (5 equivalent) was carefully added to the previous solution. The reaction was stirred at room temperature for 24 hours and monitored by TLC (cyclohexane / ethyl acetate 3:2). The solution was poured into acidified water (1M HCl) and extracted with ethyl acetate. The organic phase was collected and washed with 20% NaHCO3 solution and brine, then dried over magnesium sulfate, filtered and evaporated in vacuo.
[0408] Embodiment 21
[0409] Methyl(5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-isoleucine-L-valine Preparation of methyl ester (7a)
[0410] [Chemical formula 52]
[0411]
[0412] The crude product was prepared according to General Procedure F starting from 6a (0.091 g, 0.19 mmol), L-valine methyl ester (0.064 g, 0.38 mmol) and purified by precipitation in ethyl acetate and a small amount of cyclohexane, then washed with diethyl ether to provide 7a (0.042 g, 37%). 29 H 33 BrN2O7.
[0413] 11H NMR (400 MHz, DMSO) δ 8.79 (d, J = 8.4 Hz, 0.5H), 8.60 - 8.50 (m, 1H), 8.45 (d, J = 7.2 Hz, 0.5H), 8.13 (d, J = 7.5 Hz, 1H), 7.81 (t, J = 8.0 Hz, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.52 (t, J = 7.3 Hz, 1H), 7.40 (d, J = 8.1 Hz, 1H), 7.33 (t, J = 7.3 Hz, 1H), 7.16 (d, J = 8,4 Hz, 1H), 6.72 (d, J = 5.0 Hz, 1H), 5.25 (s, 2H), 4.73 - 4.65 (m, 0.5H), 4.54 - 4.45 (m, 0.5H), 4.27 - 4.21 (m, 0.5H), 4.21 - 4,14 (m, 0.5H), 3.65 (d, J = 4.7 Hz, 3H), 2.13 - 1.92 (m, 2H), 1.64 - 1.47 (m, 1H), 1.28 - 1.14 (m, 1H), 1.04 - 0.70 (m, 12H).
[0414] 13 13C NMR (101 MHz, DMSO) δ 172.31, 171.91, 171.88, 157.84, 157.83, 157.82, 157.51, 157.49, 157.46, 157.43, 157.42, 153.69, 153.67, 153.65, 135.92, 132.79, 130.34, 129.78, 128.33, 121.94, 114.74, 114.72, 114.70, 114.66, 112.89, 112.87, 112.69, 111.52, 111.46, 109.48, 109.46, 109.37, 109.35, 70.33, 70.31, 58.31, 58.30, 58.21, 58.05, 58.02, 57.96, 52.33, 52.26, 52.23, 52.21, 36.32, 30.00, 25.02, 19.31, 19.17, 19.13, 18.66, 18.59, 15.29, 15.28, 10.85.
[0415] HRMS (ESI / QTOF):
[0416] Calculated for C 29 H 34 BrN2O7 (M + H + ): 601.1549,
[0417] Found: 601.1533.
[0418] Embodiment 22
[0419] Methyl (5-((2-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-isoleucine-L-leucine Preparation of amino acid (7b)
[0420] [Chemical formula 53]
[0421]
[0422] The crude product was prepared according to General Procedure F starting from 6a (0.082 mg, 0.16 mmol), L-leucine methyl ester (0.061 g, 0.32 mmol) and purified by precipitation in ethyl acetate and a small amount of cyclohexane, followed by washing with ether to give 7b (0.030 g, 31%). 30 H 35 BrN2O7.
[0423] 1 H NMR (400MHz, DMSO) δ8.79(d,J=8.8Hz,0.5H),8.64(d,J=7.6Hz,1H),8.56(d,J=7.7Hz,0.5H),8.13(d,J=7.6Hz,1 H),7.81(t,J=8.2Hz,1H),7.69(d,J=8.0Hz,1H),7.52(t,J=7.5Hz,1H),7.40(dd,J=8.3,4.4Hz,1H),7.33(t,J=7, 5Hz,1H),7.16(d,J=8.1Hz,1H),6.73(d,J=7.3Hz,1H),5.25(s,2H),4.64-4.56(m,0.5H),4.41(t,J=8.7Hz,1H), 4,37-4.27(m,0.5H),3.63(s,1H),2.05-1.92(m,1H),1.74-1.43(m,4H),1.27-1.13(m,1H),0.98-0.81(m,12H)).
[0424] 13C NMR (126MHz, DMSO) δ177.64,174.72,173.46,173.29,171.55,171.48,159.81,159.64,157.82,157.41,1 53.65,153.63,135.89,135.84,132.77,130.31,129.75,128.32,121.89,114.67,112.93,112.88,111.5 0,109.43,70.31,58.05,57.49,52.53,52.42,52.32,51.52,51.02,50.90,41.57,40.89,37.32,36.39,25.92,24.96,24.70,24.64,23.10,23.01,22.99,21.82,21.57,21.44,21.23,15.31,14.95,11.64,10.85.
[0425] HRMS(ESI / QTOF):
[0426] Calculate C 30 H 36 BrN2O7(M+H + ): 615.1690,
[0427] Found: 615.1684.
[0428] Embodiment 23
[0429] Methyl (5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-isoleucine-L-valeric acid Preparation of amino acid methyl ester (7c)
[0430] [Chemical formula 54]
[0431]
[0432] The crude product was prepared according to General Procedure F starting from 6a (0.123 g, 0.25 mmol), L-valine methyl ester (0.084 g, 0.50 mmol) and purified by trituration in diethyl ether to afford 7c (0.061 g, 41%). 29 H 33 BrN2O7.
[0433] 1H NMR (400MHz, DMSO) δ8.76(d,J=8.6Hz,0.5H),8.54(d,J=9.4Hz,1H),8.43(d,J=7.5Hz,0.5H),7.76(t,J=8 ,3Hz,1H),7.60(q,J=8.6Hz,4H),7.35(d,J=8.2Hz,1H),7.11(d,J=8.3Hz,1H),6.69(d,J=5.4Hz,1H)2H),4 .67(dd,J=8.8,6.9Hz,0.5H),4.48(t,J=8.8Hz,0.5H),4.22(dd,J=7.9,6.9Hz,0.5H),4.15(t,J=7.0Hz,0 ,5H),3.63(d,J=4.9Hz,3H),2.12-1.90(m,2H),1.59-1.36(m,1H),1.25-1.11(m,1H),0.99-0.81(m,12H).
[0434] 13 C NMR (101MHz, DMSO) δ176.43,171.93,171.64,170.88,170.67,159.10,158.94,157. 64,157.01,153.21,136.29,134.90,131.19,128.91,120.58,114.52,112.61,112.5 4,110.83,109.00,69.21,57.66,57.42,57.24,56.72,51.72,51.53,37.09,35.99,29.85,29.58,25.65,24.62,19.02,18.84,18.35,18.20,14.95,14.58,11.37,10.55.
[0435] HRMS(ESI / QTOF):
[0436] Calculate C 29 H 34 BrN2O7(M+H + ):601.1549,
[0437] Found: 601.1545.
[0438] Embodiment 24
[0439] Methyl (5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carbonylamino)-L-isoleucine-L-leucine Preparation of amino acid (7d)
[0440] [Chemical formula 55]
[0441]
[0442] The crude product was prepared according to General Procedure F starting from 6b (0.123 g, 0.25 mmol), L-leucine methyl ester (0.091 mg, 0.50 mmol) and purified by trituration in ether to afford 7d (0.052 g, 34%). 30 H 35 BrN2O7.
[0443] 1 H NMR (400MHz, DMSO) δ8.76(d,J=8.7Hz,0.5H),8.62(d,J=7.8Hz,0.5H),8.54(dd,J=8.0,4.5Hz,1H),7.76( t,J=8.2Hz,1H),7.66-7.56(m,4H),7.35(dd,J=8.4,4.2Hz,1H),7.11(d,J=8.2Hz,1H),6.70(d,J=7.5Hz,1 H),5.25(s,2H),4.58(dd,J=8.6,6.5Hz,0.5H),4.39(t,J=8.6Hz,0.5H),4.36-4.24(m,1H),3.62(d,J=2. 3Hz,3H),2.03-1.89(m,1H),1.70-1.55(m,2H),1.55-1.45(m,2H),1.24-1.10(m,1H),0.96-0.79(m,12H).
[0444] 13 C NMR 176.43,172.81,172.60,170.56,170.42,159.14,158.95,157.63,157.01,15 3.19,136.28,134.90,131.19,128.91,120.57,114.51,112.62,112.54,110. 84,109.00,69.20,57.29,56.64,51.86,51.71,50.39,50.23,36.98,36.00,25.59,24.56,24.23,24.18,22.78,22.66,21.28,20.90,14.99,14.62,10.54.
[0445] HRMS(ESI / QTOF):
[0446] Calculate C 30 H 36 BrN2O7(M+H + ): 615.1690,
[0447] Found: 615.1690.
[0448] Embodiment 25
[0449] (S)-5-((2-bromophenyl)oxy)-N-(1-((2-(5-hydroxy-1H-indol-3-yl)ethyl)amino)-1-oxo Preparation of 4-oxo-3-phenylpropan-2-yl)-4-oxo-4H-chromene-2-carboxamide (Part 7)
[0450] [Chemical formula 56]
[0451]
[0452] The crude product was prepared according to General Procedure F starting from 6c (0.127 mg, 0.24 mmol), 5-hydroxytryptamine hydrochloride (0.103 mg, 0.48 mmol) and purified by trituration in methanol and then washed with ether to give 7e (0.063 g, 38%). 36 H 30 BrN3O6.
[0453] 1 H NMR (400MHz, DMSO) δ10.49(d,J=1.6Hz,1H),9.11(d,J=8.4Hz,1H),8.61(s,1H),8.31(t,J=5.5Hz,1H),8.10(dd,J=7.7,0,8H z,1H),7.79(t,J=8.4Hz,1H),7.65(dd,J=8.0,0.7Hz,1H),7.48(td,J=7.6,0.7Hz,1H),7.37-7.23(m,6H),7.18(t,J=7.2Hz, 1H),7.12(d,J=8.6Hz,2H),7.04(d,J=2.1Hz,1H),6.86(d,J=2.1Hz,1H),6.63(s,1H),6.60(dd,J=8.6,2.2Hz,1H),5.21(s,2 H), 4.73-4.65 (m, 1H), 3.34-3.26 (m, 1H), 3.17 (dd, J = 13.7, 4.5Hz, 1H), 3.05 (dd, J = 13.6, 10.2Hz, 1H), 2.73 (t, J = 7.5Hz, 2H).
[0454] 13C NMR (101 MHz, DMSO) δ 176.46, 170.03, 158.99, 157.41, 156.99, 153.19, 150.16, 137.88, 135.74, 135.14, 132.15, 130.81, 129.55, 129.15, 128.14, 127.83, 126.38, 123.13, 121.06, 114.44, 112.36, 111.65, 111.27, 110.93, 110.64, 108.83, 102.20, 69.74, 54.91, 37.11, 25.14.31 C+2EQ 3C missing.
[0455] HRMS(ESI / QTOF):
[0456] Calculate C 36 H 31 BrN3O6(M+H + ): 680.1396,
[0457] Found: 680.1392.
[0458] Embodiment 26
[0459] (S)-N-(1-((2-(1H-indol-3-yl)ethyl)amino)-1-oxo-3-phenylpropan-2-yl)-5-((4-bromo Preparation of (4-(phenyl)oxy)-4-oxo-4H-chromene-2-carboxamide (7f)
[0460] [Chemical formula 57]
[0461]
[0462] The crude product was prepared according to General Procedure F starting from 6d (0.090 g, 0.17 mmol), tryptamine hydrochloride (0.067 g, 0.34 mmol) and purified by trituration in ethyl acetate and a small amount of cyclohexane, then washed with ether to give 7f (0.014 g, 12%). 36 H 30 BrN3O5.
[0463] 1H NMR(400MHz, CDCl3)δ8.20(s,1H),7.68(d,J=7.7Hz,1H),7.57(t,J=8.4Hz,1H),7.54-7.44(m,5H),7, 32-7.15(m,6H),7.12-7.06(m,2H),7.06-7.01(m,1H),6.89(s,1H),6.85(d,J=8.2Hz,1H),6.80(s,1H ),5.99-5.91(m,1H),5.19(s,2H),4.72(dd,J=13.5,7.7Hz,1H),3.53(dd,J=11.8,5.9Hz,2H),3.20(d d,J=13.4,5.6Hz,1H),3.06(dd,J=13.3,8.4Hz,1H),2.88(dt,J=13.1,6.4Hz,1H),2.84-2.73(m,1H).
[0464] 13 C NMR (101MHz, CDCl3) δ177.67,170.09,159.03,158.55,157.39,152.34,136.50, 136.16,135.38,134.72,131.87,129.44,128.91,128.45,127.44,127.17,122.3 2,122.19,121.84,119.59,118.58,115.56,113.88,112.34,111.42,110.84,109.06,70.35,60.54,55.24,39.94,38.96,29.82,25.00,21.18,14.33.36C, instead of 32.
[0465] HRMS(ESI / QTOF):
[0466] Calculate C 36 H 31 BrN3O5(M+H + ):664.1447,
[0467] Found: 664.1432.
[0468] Embodiment 27
[0469] (R)-N-(1-((2-(1H-indol-3-yl)ethyl)amino)-3-(1H-indol-3-yl)-1-oxopropane-2- Preparation of 4-(4-bromophenyl)oxy)-5-((4-bromophenyl)oxy)-4-oxo-4H-chromene-2-carboxamide (7 g)
[0470] [Chemical formula 58]
[0471]
[0472] The crude product was prepared according to General Procedure F starting from 6e (0.069 g, 0.13 mmol), tryptamine hydrochloride (0.048 g, 0.25 mmol) and purified by trituration in ether to afford 7g (0.051 mg, 59%). 38 H 31 BrN4O5.
[0473] 1 H NMR (400MHz, DMSO) δ10.83(s,2H),8.98(d,J=8.2Hz,1H),8.34(t,J=5.3Hz,1H),7.78(t,J=8,4 Hz,1H),7.70(d,J=7.7Hz,1H),7.60(q,J=8.6Hz,1H),7.55(d,J=7.8Hz,1H),7.36-7.26(m,3H) ,7.18(dd,J=31.1,0.9Hz,2H),7.11(d,J=8.4Hz,1H),7.08-7.01(m,2H),7.00-6.92(m,2H),6.61(s,1H),5.24(s,2H),4.72-4.63(m,1H),3.30-3.14(m,2H),2.82(t,J=7.3Hz,2H). Two signals under the water peak.
[0474] 13 C NMR (101 MHz, DMSO) δ 176.46, 170.44, 158.90, 157.64, 156.94, 153.16, 136.27, 136.19, 136.04, 134.99, 131.20, 128.90, 127.24, 127.15, 123.76, 122.67, 120.89, 120.88, 120.58, 118.53, 118.21, 114.43, 112.31, 111.66, 111.33, 110.67, 110.08, 108.95, 69.17, 54.44, 27.38, 25.02.32 C+2EQ 4C missing.
[0475] HRMS(ESI / QTOF):
[0476] Calculation: C 38 H 31 BrN4O5(M+H + ):703.1556,
[0477] Found: 703.1553.
[0478] Examples 28 to 36
[0479] Series 3
[0480] [Chemical formula 59]
[0481]
[0482] NOTE: In the following protocol, "molecule number + a" refers to when the bromine is located at positions 2 and 4 of the aromatic ring, and "molecule number + b" refers to when the bromine is located at positions 3 and 5 of the aromatic ring.
[0483] General operation mode A:
[0484] 2,5-Dihydroxyacetophenone 3 (1 eq) was dissolved in acetone (11 mL / mmol). K2CO3 (3 eq) and tetra-n-butylammonium bromide (TBAB) (1.5 eq) were then mixed together, weighed and added to the solution. The resulting suspension was refluxed for 30 min and a solution of dibromo-1-(bromomethyl)benzene (1 eq) in acetone (4 mL / mmol) was added. The suspension was refluxed for 30 min and then concentrated under vacuum. The reaction was monitored by TLC (cyclohexane / ethyl acetate 7:3).
[0485] The reaction mixture was poured into ethyl acetate and acidified water (1M HCl). The aqueous layer was extracted with ethyl acetate (3 times), and then the combined organic layers were washed with acidified water (1M HCl) and salt water (1 time). The combined organic layers were dried over MgSO4, filtered and evaporated under vacuum. Finally, the crude product was dried under high vacuum.
[0486] General Procedure B:
[0487] Sodium (6 eq.) was dissolved in cold anhydrous ethanol (3 mL / mmol) to obtain a fresh sodium glycolate solution. This solution was added dropwise to a cold (0°C) solution of 4 (1 eq.) in dry THF (same volume as ethanol). Diethyl oxalate (4 eq.) was then added to the solution and stirred at room temperature for 30 minutes. The resulting solution was heated to 50°C and monitored by TLC (cyclohexane / ethyl acetate 3:2). The reaction intermediate precipitated during the reaction.
[0488] After 4 hours, 37% hydrochloric acid was added dropwise to the solution until the precipitate turned white. After the color change, the reaction was refluxed for 1.5 hours. The reaction mixture was then evaporated and poured into ethyl acetate and acidified water (1M HCl). The aqueous layer was extracted with ethyl acetate (3 times) until the color changed. The combined organic layers were washed with acidified water (1M HCl) and brine (once) and dried over MgSO4 before evaporation.
[0489] General operating procedure C:
[0490] K2CO3 (1.3 eq.) in water (15 mL / mmol) was added to a solution of 5 (1 eq.) in THF (30 mL / mmol) and ethanol (ethanol) (10 mL / mmol). The resulting solution was heated to 50°C and stirred for 1.5 hours. The reaction was monitored by TLC (cyclohexane / ethyl acetate 7:3). The reaction mixture was concentrated and poured into dichloromethane and acidified water (1 M HCl).
[0491] To increase the solubility of the desired product in the organic layer, a few drops of methanol were added. The aqueous layer was extracted with dichloromethane (3 times), and the combined organic layers were washed with acidified water (1M HCl) and brine (once). The combined organic layers were then dried over MgSO4, filtered and evaporated.
[0492] Embodiment 28
[0493] Preparation of 2,4-dibromo-1-(bromomethyl)benzene (2)
[0494] [Chemical formula 60]
[0495]
[0496] 2,4-Dibromotoluene 1 (1000 g, 4,00 mmol) and freshly purified N-bromosuccinimide (NBS) (0925 g, 5,20 mmol) were dissolved in 12 mL of 1,2-dichloroethane under an inert atmosphere. The solution was refluxed for 10 minutes, and azobisisobutyronitrile (AIBN) (0.328 g, 2.00 mmol) was added. The resulting suspension was stirred and refluxed for 6 hours. The reaction was monitored by TLC (100% cyclohexane). The reaction mixture was then evaporated, and a cold 1:1 cyclohexane / dichloromethane solution was added to precipitate the by-product (white solid). After filtration and evaporation, the crude product 2 (1.476 g, 4.49 mmol) was used directly without purification. C7H5Br3
[0497] Embodiment 29
[0498] Preparation of 1-(2-((2,4-dibromophenyl)oxy)-6-hydroxyphenyl)ethan-1-one (4a)
[0499] [Chemical formula 61]
[0500]
[0501] The crude product was prepared starting from 2 (1.315 g, 4.00 mmol) and 3 (1.000 g, 4.00 mmol) according to General Procedure A. The crude product was precipitated with 1:1 cyclohexane / dichloromethane solution and then recrystallized from isopropanol to give 4a (0.793 g, 50%). 15 H 12 Br2O3.
[0502] 1 H NMR (400MHz, DMSO) δ11.64(s,1H),7.95(d,J=1.8Hz,1H),7.66(dd,J=8.2,1.8Hz,1H),7.54(d,J=8,2H z, 1H), 7.32 (t, J = 8.3Hz, 1H), 6.62 (d, J = 8.3Hz, 1H), 6.55 (d, J = 8.2Hz, 1H), 5.13 (s, 2H), 2.45 (s, 3H).
[0503] 13 C NMR (101MHz, DMSO) δ203.27,159.54,157.71,134.92,134.60,133.83,132.06,131.01,123.92,122.19,114.68,109.93,103.16,69.38,32.88
[0504] HRMS (ESI / LTQ Trap Mass Spectrometry):
[0505] Calculate C 15 H 11 O3Br2(MH + ): 396.9080,
[0506] Found: 96.9082.
[0507] Embodiment 30
[0508] Preparation of 1-(2-((3,5-dibromophenyl)oxy)-6-hydroxyphenyl)ethan-1-one (4b)
[0509] [Chemical formula 62]
[0510]
[0511] The crude product was prepared starting from 1,3-dibromo-5-(bromomethyl)benzene (1.315 g, 4.00 mmol) and 3 (1.000 g, 4.00 mmol) according to General Procedure A. The crude product was purified by trituration in diethyl ether to afford 4b (1.103 g, 70%). 15 H 12 O3Br2.
[0512] 1H NMR (400MHz, DMSO) δ11.53(s,1H),7.79(s,1H),7.69(d,J=1.5Hz,2H),7.29(t,J=8.3 Hz,1H),6.58(d,J=8.3Hz,1H),6.54(d,J=8.2Hz,1H),5.17(s,2H),2.53-2.46(m,5H)
[0513] 13 C NMR (101MHz, DMSO) δ203.16,158.98,157.30,141.43,133.41,132.81,129.45,122.49,115.30,109.78,103.40,68.24,32.91
[0514] HRMS (ESI / LTQ Trap Mass Spectrometry):
[0515] Calculate C 15 H 11 O3Br2(MH + ):396.9080,
[0516] Found: 396.9078.
[0517] Embodiment 31
[0518] Preparation of ethyl 5-((2,4-dibromophenyl)oxy)-4-oxo-4H-chromene-2-carboxylate (5a)
[0519] [Chemical formula 63]
[0520]
[0521] The crude product was prepared starting from 4a (0.435 g, 1.09 mmol) and diethyl oxalate (0.636 g, 4.35 mmol) according to the general procedure B. The resulting oil solidified under high vacuum and isopropanol was added and heated.
[0522] The resulting suspension was filtered and the paste product was dissolved in dichloromethane and evaporated to obtain a white solid. The desired product 5a (0.144 g, 27%). 19 H 14 O5Br2.
[0523] 1H NMR (400MHz, DMSO) δ8.08(d,J=8.3Hz,1H),7.94(d,J=1.9Hz,1H),7.80(t,J=8.4Hz,1H),7.74(dd,J=8.3,1.9Hz,1H) ,7.29(d,J=8.5Hz,1H),7.15(d,J=8.3Hz,1H),6.81(s,1H),5.19(s,2H),4.40(q,J=7.1Hz,2H),1.36(t,J=7.1Hz,3H)
[0524] 13 C NMR(101MHz,DMSO)δ176.44,159.99,157.23,157.22,150.30,135.46,135.43,134.04, 130.85,130.60,121.82,121.29,115.42,114.59,110.90,108.90,69.29,62.62,13.87
[0525] HRMS (ESI / LTQ Trap Mass Spectrometry):
[0526] Calculate C 19 H 15 O5Br2(M+H + ):480.9281,
[0527] Found: 480.9271.
[0528] Embodiment 32
[0529] Preparation of ethyl 5-((3,5-dibromophenyl)oxy)-4-oxo-4H-chromene-2-carboxylate (5b)
[0530] [Chemical formula 64]
[0531]
[0532] The crude product was prepared starting from 4b (1.103 g, 2.76 mmol) and diethyl oxalate (1.612 g, 14.03 mmol) according to the general procedure B. The crude product was purified by trituration in diethyl ether to afford 5b (0.785 g, 59%). 19 H 14 Br2O5.
[0533] 1H NMR(400MHz,DMSO)δ7.91(d,J=1.6Hz,2H),7.81-7.74(m,2H),7.26(d,J=8.1Hz,1H),7,08 (d, J=8.3Hz, 1H), 6.83 (s, 1H), 5.27 (s, 2H), 4.38 (q, J=7.1Hz, 2H), 1.34 (t, J=7.1Hz, 3H).
[0534] 13 C NMR(101MHz,DMSO)δ176.55,159.99,157.32,157.22,150.28,141.68,135.40, 132.26,128.38,122.44,115.46,114.62,110.82,108.83,68.21,62.60,13.86
[0535] HRMS (ESI / LTQ Trap Mass Spectrometry):
[0536] Calculate C 19 H 15 Br2O5(M+H + ): 480.9281,
[0537] Found: 480.9274.
[0538] Embodiment 33
[0539] Preparation of 5-((2,4-dibromophenyl)oxy)-4-oxo-4H-chromene-2-carboxylic acid (6a)
[0540] [Chemical formula 65]
[0541]
[0542] The crude product was prepared according to General Procedure C starting from 5a (0.144 g, 0.30 mmol) and purified by trituration in 1:1 ether / dichloromethane to afford 6a (0.074 g, 55%). 17 H 10 Br2O5.
[0543] 1 H NMR (400MHz, DMSO) δ8.07(d,J=8.3Hz,1H),7.90(d,J=1.9Hz,1H),7.76(t,J=8.4Hz,1H),7,70( dd,J=8.3,1.9Hz,1H),7.24(d,J=8.3Hz,1H),7.10(d,J=8.3Hz,1H),6.75(s,1H),5.15(s,2H).
[0544] 13 C NMR (101MHz, DMSO) δ176.72,161.42,157.30,157.17,151.21,135.46,135.28,133. 97,130.81,130.55,121.71,121.23,115.20,114.54,110.90,108.69,69.23,64.89
[0545] HRMS (ESI / LTQ Trap Mass Spectrometry):
[0546] Calculate C 17 H 11 Br2O5(M+H + ): 454.8948,
[0547] Found: 454.8937.
[0548] Embodiment 34
[0549] Preparation of 5-((3,5-dibromophenyl)oxy)-4-oxo-4H-chromene-2-carboxylic acid (6b)
[0550] [Chemical formula 66]
[0551]
[0552] The crude product was prepared according to General Procedure C starting from 5b (0.785 g, 1.63 mmol) and purified by trituration in 1:1 ether / dichloromethane to afford 6b (0.493 g, 67%). 17 H 10 Br2O5.
[0553] 1 H NMR (400MHz, DMSO) δ7.91(s,2H),7.82-7.72(m,2H),7.24(d,J=8.4Hz,1H),7.06(d,J=8.3Hz,1H),6.79(s,1H),5.27(s,2H)
[0554] 13 C NMR (101MHz, DMSO) δ176.82,161.44,157.31,157.29,151.21,141.70,135.23,132.22,128.34,122.42,115.23,114.58,110.83,108.67,68.19
[0555] HRMS (ESI / LTQ Trap Mass Spectrometry):
[0556] Calculate C17 H 11 Br2O5(M+H + ): 454.8948,
[0557] Found: 454.8941.
[0558] Embodiment 35
[0559] 5-(2,4-dibromophenyl)oxy)-N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-oxo-4H- Preparation of olefin-2-carboxamide (7a)
[0560] [Chemical formula 67]
[0561]
[0562] 6a (0.074 g, 0.16 mmol) was dissolved in 2 mL of anhydrous DMF. Subsequently, DIEA (0.084 g, 0.65 mmol) and TBTU (0.105 g, 0.33 mmol) were added to the solution in sequence. After complete dissolution, 5-methoxytryptamine (0.074 g, 0.33 mmol) was added and the resulting solution was stirred at room temperature for 24 hours. The reaction was monitored by TLC (cyclohexane / ethyl acetate 1:4).
[0563] The reaction mixture was poured into acidified water (1M HCl) and extracted with dichloromethane (3 times). The organic phases were collected and washed with acidified water (1M HCl), basified water (10% NaOH) and brine (once), then dried over MgSO4, filtered and evaporated. The resulting oil was precipitated with a few drops of ether.
[0564] After filtration, the crude product was purified using a 12 g silica gel column with cyclohexane / dichloromethane 4:1 to 100% dichloromethane as eluent. After the first product eluted, 9:1 dichloromethane / methanol was used to obtain the desired product. The desired product 7a (0.006 g, 5.6%) was obtained as a solid. 28 H 22 Br2N2O5
[0565] 1 H NMR (500MHz, CDCl3) δ8.12(d,J=8.4Hz,1H),8.00(s,1H),7.72(d,J=1.9Hz,1H),7.60-7.55(m,2H),7.31(d,J=8.8Hz,1H),7.10(dd,J =9.8,2.3Hz,2H),7.05(s,1H),6.95-6.89(m,3H),6.85(dd,J=8.4,0.5Hz,1H),5.16(s,2H),3.84-3.78(m,5H),3.11(t,J=6.6Hz,2H)
[0566] 13 C NMR (126MHz, CDCl3) δ177.59,159.14,158.11,157.22,154.32,152.90,134.78,134.48,134.36,131.54,131.28,130.13,12 7.80,122.96,121.80,121.15,115.29,113.68,112.63,112.36,112.17,110.59,108.41,100.40,69.86,55.84,40.52,24.94
[0567] HRMS (ESI / LTQ Trap Mass Spectrometry):
[0568] Calculate C 28 H 23 Br2N2O5(M+H+):626.9948,
[0569] Found: 626.9929.
[0570] Embodiment 36
[0571] ((3,5-dibromophenyl)oxy)-N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-oxo-4H-chromatographic Preparation of olefin-2-carboxamide (7b)
[0572] [Chemical formula 68]
[0573]
[0574] 6b (0.100 g, 0.22 mmol) was dissolved in anhydrous DMF (10 mL) and stirred until completely dissolved. (1H-benzotriazol-1-yloxy)(tris-1-pyrrolidinyl)phosphine hexafluorophosphate (PyBOP) coupling agent (0.195 g, 0.44 mmol) was then added to the solution, followed by DIEA (0.114 g, 0.88 mmol). The solution was stirred at room temperature for 1 hour. A color change occurred.
[0575] Then 5-methoxytryptamine (0.100 g, 0.44 mmol) was added and the solution was stirred at room temperature for 2 days. In the case of no change in cyclohexane / ethyl acetate 1:1 thin layer chromatography, bis(2-oxo-1,3-oxazolidin-3-yl)phosphine chloride (BOP-Cl) (0.112 g, 0.44 mmol) was added to the solution. After 2 days, 1:1 cyclohexane / ethyl acetate thin layer chromatography showed product formation.
[0576] The reaction mixture was evaporated and poured into ethyl acetate. The organic phase was washed with basified water (saturated K2CO3), then acidified water (1M HCl) and brine (3 times). The organic layer was dried over MgSO4 and evaporated to obtain a brown solid.
[0577] The solid was purified by silica gel column chromatography using the dried sample and eluent (e.g. 100% dichloromethane, then 2.4:0.1 dichloromethane / methanol). A 5 mL fraction was stored in a fume hood overnight to precipitate the desired product. After filtration, the desired product 7b (0.007 g, 6.6%) was obtained. 28 H 22 O5N2Br2
[0578] 1 H NMR (400MHz, DMSO) δ10.71(s,1H),9.23(t,J=5.8Hz,1H),7.94(d,J=1.3Hz,2H),7.85-7.79(m,2H),7.30(d,J=8.4Hz,1H),7.24(d,J=8.7Hz,1 H),7.19(d,J=2.1Hz,1H),7.12-7.06(m,2H),6.76-6.70(m,2H),5.30(s,2H),3.75(s,3H),3.58(dd,J=14.2,6.6Hz,2H),2.97(t,J=7.4Hz,2H)
[0579] 13 C NMR (126MHz, DMSO) δ177.14,159.37,157.83,157.49,154.21,153.51,142.26,135.54,132.78,131.88,128.94, 128.03,123.91,122.94,114.95,112.57,112.53,111.72,111.56,111.36,109.32,100.65,68.76,55.81,25.35
[0580] HRMS (ESI / LTQ Trap Mass Spectrometry):
[0581] Calculate C 28 H 23 O5N2Br2(M+H + ): 626.9948,
[0582] Found: 26.9937.
[0583] Embodiment 37
[0584] Biological evaluation
[0585] Material
[0586] High glucose DMEM (Dulbecco / Vogt modified Eagle's minimum medium) and GlutaMAX TM (Gibco) and fetal bovine serum (FBS, GE Healthcare Hyclone) were purchased from Fisher Scientific. Penicillin / streptomycin (10000U / 10mg / ml), G418, trypsin and Dulbecco's phosphate buffered saline (DPBS) were purchased from Sigma-Aldrich (France), as well as mitoxantrone (MX), rhodamine 123 (R123), calcein AM (cAM) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). All commercial products were of the highest purity.
[0587] Compound
[0588] All chromone derivatives were dissolved in dimethyl sulfoxide (DMSO) and then diluted in high glucose DMEM. Stock solutions were stored at -20 °C and warmed to 25 °C before use.
[0589] Cell lines and cultures
[0590] ABCB1 transfected NIH / 3T3, ABCC1 transfected Flp-In 293 and ABCG2 transfected HEK293 cells and their empty plasmid counterparts were generated as described previously (Borst, P.; Elferink, ROMammalian ABC Transporters in Health and Disease. Annu. Rev. Biochem. 2002, 71(1), 537-592).
[0591] Specifically, ABCG2-transfected HEK293 monoclonal cell lines were selected after fluorescence-activated cell sorting (FACS) using phycoerythrin-conjugated 5D3 antibody (Santa Cruz Biotech) as an endogenously expressed reporter gene.
[0592] Cells were cultured in GlutaMAX medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1% penicillin / streptomycin at 37°C in a humidified atmosphere containing 5% CO2. TM In addition, 200 μg / mL hygromycin B, 90 ng / mL colchicine, or 750 μg / mL G418 were added to the growth medium as selection agents for NIH / 3T3, Flp-In293, or HEK293 transfected cells, respectively.
[0593] Cytotoxicity assay
[0594] The cytotoxicity of the compounds was determined using the colorimetric MTT method as described in the following literature (Linton, KJ Structure and Function of ABC Transporters. Physiology 2007, 22(2), 122-130. Sharom, FJABC Multidrug Transporters: Structure, Function and Role in Chemoresistance. Pharmacogenomics 2008, 9(1), 105-127).
[0595] Briefly, cells were counted at 1×10 5 Cells were seeded at a density of 100 cells / well in a 96-well plate in a total growth medium volume of 100 μL and cultured overnight. Then, 100 μL of fresh medium containing increasing concentrations of the test compound (dissolved in DMSO at a concentration range of 0, 2, and 20 μM) was added to each well, while the DMSO control was fixed at 0.5% (v / v). After 72 hours of culture, 22 μL of MTT dye (5 mg / mL) in PBS was added to each well, and the culture plates were incubated for another 4 hours at 37°C. After the medium was removed and dried, the formazan was dissolved with 200 μL of DMSO / ethanol (1:1, v / v). Dye crystals. Absorbance was measured spectrophotometrically with reference wavelengths at 570 nm and 690 nm. The effect of each compound on cell viability in all cell lines was calculated as the difference in absorbance between wells with test medium and wells with control medium.
[0596] The cytotoxicity results of the compounds according to the present invention are shown in Table 1.
[0597]
[0598]
[0599] Therefore, the compounds according to the present invention have very low or no cytotoxicity.
[0600] Multidrug resistance-related drug efflux inhibition assay
[0601] The cells were seeded at a density of 5 x 10 4Cells were plated in 96-well plates with 10 cells / well and incubated overnight in 200 μL of medium. The growth medium was then changed to fresh medium containing the compound and in the presence of 4 μM MX at a final concentration of 0.5% (v / v) DMSO as a fluorescent probe for BCRP-mediated efflux. After 30 min of incubation at 37°C, the medium was removed and the cells were washed with 100 μL Dulbecco's phosphate-buffered saline (DPBS) and then detached in 25 μL of trypsin at 37°C for 5 min. Finally, trypsin was neutralized with 175 μL ice-cold DPBS and 2% bovine serum albumin (BSA) and the cells were carefully resuspended. As a selective test, the same experiment was performed for P-gp- and MRP1-mediated efflux using 0.5 μM R123 or 0.2 μM cAM as the respective fluorescent substrates instead of MX.
[0602] Intracellular fluorescence was measured using a MacsQUANT VRB Analyzer flow cytometer (Miltenyi Biotec), and at least 5000 events were recorded. MX was excited at 635 nm, and fluorescence emission was recorded in the 655-730 nm window, while R123 and cAM were excited at 488 nm and recorded in a 525 / 50 nm filter. Compound inhibition was estimated by the following equation:
[0603] [Mathematical formula 1]
[0604]
[0605] Among them, G 2FA G2 is the fluorescence emission (au) of the accumulated fluorophore in cells expressing the efflux pump incubated with the fluorescent substrate and the test compound. FBG is the background fluorescence emission (au) produced in cells transfected with ABCG2 (without substrate or test compound). S is the fluorescence emission (au) of the accumulated fluorophore in cells expressing the efflux pump incubated with substrate only. FA is the fluorescence emission (au) of the accumulated fluorophore in control cells incubated with substrate and test compound. FBG is the background fluorescence emission (au) produced in control cells (no substrate or test compound). All values are given as the geometric mean fluorescence emission (au) in a 655-730 nm filter (635 nm excitation), measured in 5000 events. The experiment was performed in triplicate.
[0606] Activity of chromones as ABCG2 inhibitors
[0607] [Table 2]
[0608]
[0609] The above table shows that the compounds showed good IC50 values. In particular, compound 5d in series 1, compounds 7a and 7b in series 2, and compound 7a in series III showed better results than the MBL-II-141 inhibitor and the reference inhibitor Ko143.
[0610] Chromone selectivity of BCRP versus P-gp and MRP1
[0611] [Table 3]
[0612]
Claims
1. A compound, characterized in that Selected from: [Compound 5a of Series 1] [Compound 5c of Series 1] [Compound 5d of Series 1] [Compound 5e of Series 1] [Compound 5f of Series 1] [Compound 5h of Series 1] [Compound 5i of Series 1] [Compound 7a of Series 2] [Compound 7b of Series 2] [Compound 7c of Series 2] [Compound 7d of Series 2] [Compound 7a of Series 3] [Compound 7b of Series 3] 2. Use of the compound as claimed in claim 1 in the preparation of a drug for inhibiting multidrug resistance protein in breast cancer.
3. The use according to claim 2, characterized in that: The multidrug resistance protein is the breast cancer resistance protein BCRP / ABCG2.
4. A pharmaceutical composition comprising: at least one pharmaceutically acceptable active agent; and At least one compound as claimed in claim 1.
5. The pharmaceutical composition according to claim 4, characterized in that The pharmaceutically acceptable active agent is selected from anticancer agents, intestinal anti-inflammatory agents, cholesterol-lowering agents, anti-dyslipidemia agents and kinase inhibitors.
